LPDE4 inhibitor - Bayer
Latest Information Update: 24 Aug 2004
At a glance
- Originator Bayer
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 24 Aug 2004 No development reported - Preclinical for Chronic obstructive pulmonary disease in Europe (PO)
- 23 Oct 2001 Preclinical development for Chronic obstructive pulmonary disease in Europe (PO)